{"id":"W2486629951","doi":"10.1016/s1470-2045(16)30206-6","title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2995,"is_retracted":false,"has_abstract":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Multiple myeloma; Minimal residual disease; Medicine; Bone marrow; Myeloma protein; Clinical trial; Disease; Oncology; Monoclonal; Internal medicine; Monoclonal antibody; Immunology; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}